Summary
Pfizer Inc. (PFE) announced on February 9, 2015, that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. to buy back $5 billion of its own common stock. This strategic move is consistent with Pfizer's previously authorized share repurchase program and indicates management's confidence in the company's valuation and future prospects. Approximately 150 million shares are expected to be received by Pfizer on February 11, 2015. The final settlement, anticipated by the third quarter of 2015, will adjust the total repurchase based on the volume-weighted average stock price during the term. This action aims to return value to shareholders, potentially increasing earnings per share by reducing the outstanding share count.
Key Highlights
- 1Pfizer entered into a $5 billion accelerated share repurchase (ASR) agreement.
- 2The ASR agreement is with Goldman, Sachs & Co.
- 3Approximately 150 million shares are expected to be delivered on February 11, 2015.
- 4The ASR program is in line with a previously announced share repurchase authorization.
- 5Final settlement is expected by the third quarter of 2015.
- 6The final number of shares repurchased will be subject to adjustments based on the volume-weighted average stock price.